Navigation Links
Oramed Pharmaceuticals Completes $5.6 Million Funding to Advance Clinical Trials
Date:12/11/2012

JERUSALEM, December 11, 2012 /PRNewswire/ --

Oramed Pharmaceuticals Inc. (OTCBB:ORMP) (http://www.oramed.com), a developer of oral drug delivery systems, announced today that it has completed a capital raise of $4,973,075, net of finder's fee, priced at $0.37 per unit. Each unit includes one share of stock. Unit holders were also issued one warrant for each two shares of stock purchased, at an exercise price of $0.50 per share for five years. A total of 13,647,866 shares of common stock and 6,823,938 warrants were issued. The Company also issued 13,514 shares of common stock and 6,757 common stock purchase warrant, and will also issue 152,939 shares of common stock and 76,470 common stock purchase warrant as a finder's fee.

In addition, on October 30, 2012, the Company issued 2,390,057 shares of common stock to D.N.A Biomedical Solutions Ltd., valued at such time at approximately $628,630, for a warrant to purchase up to 21,637,611 ordinary shares of D.N.A.

"The funds from this raise, which was done at a premium to our current and recent trading price, will afford the Company the necessary capital as it approaches Phase 2 trials on its oral insulin capsule in the U.S. We intend to file an IND (Investigative New Drug) application for the trial with the FDA in the upcoming weeks," commented Nadav Kidron, CEO of Oramed.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy securities. The securities offered and sold in the private placement have not been registered under the Securities Act of 1933, as amended (the "Securities Act"), or any state securities laws, and may not be offered or sold in the United States absent registration, or an applicable exemption from registration under the Securities Act and applicable state securities laws.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery sol
'/>"/>

SOURCE Oramed Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Oramed Pharmaceuticals to Present at the 11th National Life Science & Technology Week ILSI-BIOMED Conference; Tel Aviv, Israel, 2012
2. Oramed Pharmaceuticals Granted Core Technology Patent in New Zealand
3. Oramed Pharmaceuticals to Present at the 12th Annual Diabetes Technology Society Meeting in Bethesda, MD, Nov 8-10, 2012
4. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
5. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
6. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
7. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
8. Icahn Issues Statement Regarding Amylin Pharmaceuticals
9. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
10. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
11. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... May 22, 2013  Flagship Ventures, a leading ... healthcare and sustainability, today announced the appointment of ... Senior Partner. In this role, Mr. Bancel will ... In addition to working closely with ... serves as President and Chief Executive Officer of ...
(Date:5/22/2013)... -- Grifols, a global healthcare company based in ... demonstrating that a higher dose of PROLASTIN © -C ... alpha 1 protein in patients with alpha 1 ... the normal range for healthy individuals. AAT deficiency is ... the alpha 1 proteinase inhibitor (A1PI) protein can ...
(Date:5/22/2013)... , May 22, 2013  Ohr Pharmaceutical Inc. ... of novel therapeutics for unmet medical needs, today announced ... , M.D., Ph.D., to its Board of Directors. Dr. ... on early and late stage drug development. ... Ohr,s Board," said Dr. Irach Taraporewala, CEO of Ohr ...
Breaking Medicine Technology:Life Science Industry Veteran Stephane Bancel Joins Flagship Ventures 2Life Science Industry Veteran Stephane Bancel Joins Flagship Ventures 3Grifols study demonstrates higher dose of PROLASTIN-C increases levels of alpha1-PI to within normal range in patients with AAT deficiency 2Grifols study demonstrates higher dose of PROLASTIN-C increases levels of alpha1-PI to within normal range in patients with AAT deficiency 3Grifols study demonstrates higher dose of PROLASTIN-C increases levels of alpha1-PI to within normal range in patients with AAT deficiency 4Ohr Pharmaceutical Appoints June S. Almenoff to Board of Directors 2Ohr Pharmaceutical Appoints June S. Almenoff to Board of Directors 3
... 15 ITelagen, Inc., innovative provider of healthcare ... Medical Services, Inc., a leading regional distributor of medical supplies, equipment ... today of the final rule on "meaningful use" of an electronic ... , , ...
... July 15 Merz Aesthetics today announced it is now shipping ... only available in Europe , Asclera™ was recently approved by the ... , , ... Phlebology , leading experts conclude that polidocanol is a highly effective ...
Cached Medicine Technology:Bell Medical and ITelagen Welcome Final Rule for 'Meaningful Use' of Electronic Health Records 2Merz Aesthetics™ Asclera™ (polidocanol) Injection Now Available in Doctors' Offices Nationwide 2Merz Aesthetics™ Asclera™ (polidocanol) Injection Now Available in Doctors' Offices Nationwide 3Merz Aesthetics™ Asclera™ (polidocanol) Injection Now Available in Doctors' Offices Nationwide 4
(Date:5/22/2013)... 22, 2013 A new study published online ... that of young people who visited fast food or chain ... were obese were more likely to use calorie information given ... found that young people eating at fast food or chain ... to use calorie information as those eating there once a ...
(Date:5/22/2013)... 2013 Nearly 50,000 veterans appeals were ... fiscal year 2012, with even more—54,033—expected by fiscal year-end ... a decision as the agency reports reduced decisions and ... veterans disability appeal services. The BVA is an ... Although the BVA received 49,611 cases in FY 2012, ...
(Date:5/22/2013)... People in the United States have been ... shortages. In much of the world, water shortages are normal ... Kleyne. She warns against taking water for granted and provides ... so easily in the United States. , Sharon Kleyne is ... show, heard live or by podcast on World Talk Radio, ...
(Date:5/22/2013)... 2013 According to a May 14, 2013 ... Options for Breast Cancer Surgery,” modern medical technology has given ... this disease in a whole new light. Since the new ... face breast cancer and mastectomies with greater hope ... the introduction of plastic surgery to oncology, women had little ...
(Date:5/22/2013)... (HealthDay News) -- Over the next two decades, the ... expected to more than double, topping more than $180 ... main factor driving the increase: an aging population. The ... American Stroke Association, was published May 22 in the ... the health care system," Dr. Bruce Ovbiagele, chairman of ...
Breaking Medicine News(10 mins):Health News:STRICTLY EMBARGOED UNTIL 6:00AM EST THURSDAY May 23, 2013; Calorie Information in Fast Food Restaurants Used by 40% of 9-18 Year Olds when Making Food Choices, Study Finds 2Health News:STRICTLY EMBARGOED UNTIL 6:00AM EST THURSDAY May 23, 2013; Calorie Information in Fast Food Restaurants Used by 40% of 9-18 Year Olds when Making Food Choices, Study Finds 3Health News:Veterans Disability Appeals See Fewer Decisions in FY2012, Reports Allsup 2Health News:Water Advocate Sharon Kleyne Announces Water Conservation Appreciation 2Health News:Breast Augmentation – New Option for Breast Cancer Surgeries 2Health News:Cost of Treating Strokes in U.S. Could Soar to $180B Annually by 2030: Report 2Health News:Cost of Treating Strokes in U.S. Could Soar to $180B Annually by 2030: Report 3
... derived from a patient,s own bone marrow were safely used ... results of a Phase I clinical trial at The University ... were published in this month,s issue of Neurosurgery , ... data demonstrate that the acute harvest of bone marrow and ...
... During spring training, you will find Major League pitchers ... muscles to endure the grueling 162 game season. A ... journal of the Association for Psychological Science, suggests that ... could have on their brains. The study, led ...
... THURSDAY, March 10 (HealthDay News) -- New research challenges the ... animal species. It,s long been thought that humans, relatively ... people age more slowly than other animals. Comparisons with short-lived ... idea. But researchers who conducted the first-ever comparison of ...
... 9 (HealthDay News) -- The U.S. Food and Drug Administration on ... than 50 years when it approved Benlysta as a way to ... directly into a vein, Benlysta is the first drug designed to ... cells believed to be at the root of lupus, the FDA ...
... When prostate cancer stem cells (CSCs) were ... SAP stopped cancer stem cell colony formation and also ... (in vitro). According to the international team of researchers ... their results in a recent issue of Cell ...
... Hopkins Children,s Center researchers have discovered that most children ... The newly identified misalignment can affect how surgeries of ... researchers say. The study will be published ... Pediatric Orthopaedics . Previous studies of patients with ...
Cached Medicine News:Health News:Pitchers bean more batters in the heat of the summer 2Health News:Humans Age at Same Pace as Other Primates, Study Finds 2Health News:FDA Approves 1st New Lupus Drug in More Than 50 Years 2Health News:Trapping prostate cancer cells to keep them from spreading provides hope 2Health News:Hopkins Children's study finds some patients with cerebral palsy have asymmetric pelvic bones 2
... VHD was the first ... bleeding after diagnostic and ... procedures. It is a ... approved for immediate sheath ...
... Ultra thin collagen coated highly ... ultra thin wall construction offers ... The Hemacarotid UltraThin Patch provides ... conformability, and healing, without suture ...
The VasoSeal Low Profile device is designed for smaller sheath angiography procedures. VasoSeal Low Profile. Seal your arterial punctures with confidence....
... technology provides a rapid mechanical ... seal that protects and preserves ... plays a role in the ... compromise to the artery or ...
Medicine Products: